Residency · Residency · Family Medicine
Contraception Counseling: A Patient-Centered Approach
Overview
Family physicians provide comprehensive contraception counseling, ensuring that patients can make informed decisions based on efficacy, safety, personal preferences, and reproductive goals. The US Medical Eligibility Criteria provides the framework for guiding safe contraceptive use across a wide range of medical conditions.
Contraceptive Efficacy (Typical Use Failure Rates)
Contraceptive methods are organized into tiers by typical-use efficacy. Tier 1 methods, with failure rates below 1%, include the copper and levonorgestrel IUDs, the etonogestrel implant, vasectomy, and tubal ligation. Tier 2 methods, with failure rates of 4 to 9%, include the injectable (DMPA) and combined hormonal methods such as the pill, patch, and ring. Tier 3 methods, with failure rates of 12 to 24%, include the male condom, diaphragm, fertility awareness methods, withdrawal, and the sponge. Emergency contraception options include ulipristal acetate, levonorgestrel, and the copper IUD.
| Tier | Typical-Use Failure Rate | Methods |
|---|---|---|
| Tier 1 | <1% | Copper IUD, LNG-IUD, implant, vasectomy, tubal ligation |
| Tier 2 | 4-9% | DMPA injection, combined pill, patch, ring |
| Tier 3 | 12-24% | Male condom, diaphragm, fertility awareness, withdrawal, sponge |
Long-Acting Reversible Contraception (LARC)
Etonogestrel Implant (Nexplanon)
The etonogestrel implant is a single subdermal rod now approved for 5 years of use, extended from the original 3 years. With 99.95% efficacy, it is the most effective reversible contraceptive available. It works primarily through ovulation suppression and cervical mucus thickening. The most common side effect is irregular bleeding, which is also the most common reason for removal. Headache and minimal weight gain may occur. It is US MEC Category 1 for most patients and can be inserted in the office setting. Insertion can occur immediately postpartum, post-abortion, or at any point in the menstrual cycle using the quick-start approach.
Levonorgestrel IUD (Mirena, Liletta, Kyleena, Skyla)
The levonorgestrel IUD is available in several formulations. Mirena and Liletta contain 52 mg of levonorgestrel, are effective for 8 years, and provide the greatest reduction in menstrual bleeding. Kyleena contains 19.5 mg, is effective for 5 years, and has a smaller frame. Skyla contains 13.5 mg, is effective for 3 years, and has the smallest frame. The mechanism is primarily local, involving cervical mucus thickening, endometrial thinning, and partial ovulation suppression. Beyond contraception, the LNG-IUD reduces menstrual bleeding (Mirena is FDA-approved for heavy menstrual bleeding), relieves dysmenorrhea, and provides endometrial protection during estrogen therapy. Side effects include irregular bleeding during the first 3 to 6 months, followed by oligomenorrhea or amenorrhea.
Copper IUD (Paragard)
The copper IUD is a hormone-free option effective for 10 years, with some evidence supporting use up to 12 years. It works through spermicidal copper ions and an inflammatory endometrial response. Side effects include heavier, longer, and more painful periods, which may improve over 6 to 12 months. When inserted within 5 days of unprotected intercourse, it serves as the most effective form of emergency contraception. It is ideal for patients desiring long-acting, hormone-free contraception.
IUD Considerations
IUDs are safe for nulliparous women, adolescents, and immediately postpartum. The expulsion rate is 2 to 10%, higher with immediate postpartum insertion. The perforation rate is approximately 1 per 1000 insertions. There is no increased risk of pelvic inflammatory disease beyond the first 20 days post-insertion. While the overall risk of ectopic pregnancy is decreased with IUD use, if pregnancy does occur with an IUD in place, a higher proportion of pregnancies are ectopic. The quick-start approach with same-day insertion is supported by evidence and eliminates the need to wait for menses.
Combined Hormonal Contraception (CHC)
Methods
Combined hormonal contraception includes the combined oral contraceptive pill containing ethinyl estradiol (20 to 35 mcg) plus a progestin taken daily, the transdermal patch (Xulane) applied weekly for 3 weeks followed by 1 week off, and the vaginal ring (NuvaRing replaced monthly; Annovera as a 1-year reusable ring).
Mechanisms
The primary mechanism is ovulation suppression, with additional effects of cervical mucus thickening and endometrial thinning.
Non-Contraceptive Benefits
Combined hormonal methods provide menstrual regulation, reduced dysmenorrhea and menorrhagia, acne improvement, hirsutism reduction, decreased ovarian and endometrial cancer risk, ovarian cyst prevention, and symptom management for endometriosis.
Risks and Contraindications (US MEC Category 4: Do NOT Use)
Category 4 contraindications, where the method should not be used, include a history of VTE, PE, or DVT; known thrombogenic mutations such as Factor V Leiden; migraine with aura (due to stroke risk); age 35 or older and smoking 15 or more cigarettes per day; uncontrolled hypertension of 160/100 or above; current breast cancer; history of ischemic heart disease or stroke; active liver disease including hepatitis, cirrhosis, and liver tumors; and fewer than 21 days postpartum regardless of breastfeeding status.
Prescribing Approach
Blood pressure measurement is the only required examination before starting combined hormonal contraception; no pelvic exam or Pap smear is needed. The quick-start method allows patients to begin on the day of the visit regardless of cycle day, with a backup method used for 7 days. Continuous or extended cycling, in which placebo pills are skipped, is safe and effective for reducing menstrual frequency.
Progestin-Only Methods
Progestin-Only Pill (POP/"Mini-Pill")
The traditional norethindrone POP must be taken within a strict 3-hour window daily. The drospirenone POP (Slynd) offers a much more forgiving 24-hour window and is emerging as the preferred progestin-only pill. Progestin-only pills have fewer contraindications than combined hormonal methods and are safe in patients with migraine with aura, hypertension, VTE history, and during breastfeeding. They are less effective than combined methods with typical use and are highly dependent on adherence.
DMPA Injection (Depo-Provera)
Medroxyprogesterone acetate is administered as 150 mg intramuscularly or 104 mg subcutaneously every 12 to 13 weeks. It is highly effective, with a 6% typical-use failure rate. Side effects include weight gain averaging 5 to 8 pounds in the first year, irregular bleeding initially followed by amenorrhea, and delayed return to fertility for up to 10 months. It carries an FDA black box warning for bone mineral density loss, which is reversible after discontinuation, with a recommendation to limit use to 2 years unless no suitable alternative exists. The subcutaneous formulation enables patient self-injection at home.
Emergency Contraception (EC)
Options
The copper IUD is the most effective emergency contraception, with a pregnancy rate below 0.1% when inserted within 5 days of unprotected intercourse. Ulipristal acetate (ella) at 30 mg as a single dose is effective up to 5 days and is more effective than levonorgestrel, especially on days 3 through 5. It requires a prescription, and hormonal contraception should be delayed for 5 days after ella due to a drug interaction. Levonorgestrel (Plan B) at 1.5 mg as a single dose is available over the counter and is most effective within 72 hours, with decreasing efficacy beyond that window. Its efficacy is reduced in women weighing more than 75 kg, for whom ella or the copper IUD should be offered instead. The Yuzpe method using a combined OCP regimen is less effective and causes more side effects, and it should only be used when other emergency contraception is unavailable.
LNG IUD for Emergency Contraception
Emerging evidence supports the LNG-IUD as effective emergency contraception, with some studies showing non-inferiority to the copper IUD. It is not yet FDA-approved for this indication but is increasingly used off-label.
US Medical Eligibility Criteria (US MEC) Framework
The US MEC framework classifies contraceptive use into four categories. Category 1 indicates no restriction, meaning the method can be used in any circumstance. Category 2 indicates that the advantages generally outweigh the risks. Category 3 indicates that the risks generally outweigh the advantages, and the method is not usually recommended. Category 4 indicates unacceptable health risk, and the method should not be used. The CDC US MEC Summary Chart and app are available as free key resources.
Shared Decision-Making and Reproductive Autonomy
All options should be presented, and directive counseling toward any specific method should be avoided. Patient priorities should be explored, including efficacy, side effects, menstrual effects, duration, reversibility, partner involvement, and cost. LARC-first counseling frameworks have been criticized for potentially undermining autonomy, especially in marginalized populations. Patient choice should be respected even when a less effective method is selected. Concerns about fertility return, side effects, and safety should be addressed with evidence-based information. Access issues including cost (ACA coverage), clinic availability, partner dynamics, and cultural factors should all be considered.
<image>A contraceptive efficacy comparison chart showing all available methods organized by tier (most to least effective), with typical-use and perfect-use failure rates displayed as bar graphs. Include icons for each method type, and color-code by category (LARC, hormonal, barrier, behavioral). Show the contraceptive effectiveness ladder format commonly used in clinical counseling.</image>
<image>A quick-reference US MEC summary table for combined hormonal contraception showing Category 1 through 4 conditions. Highlight the most clinically important Category 3 and 4 contraindications with visual icons: migraine with aura, VTE history, smoking over 35, uncontrolled hypertension, and breast cancer. Include a separate column for progestin-only methods showing their generally wider eligibility.</image>
<image>A patient counseling visual comparing the five LARC methods (copper IUD, three LNG-IUDs, implant) showing device appearance, duration of use, effect on menstrual bleeding, hormonal vs non-hormonal status, size comparison, and ideal patient profile for each. Use a side-by-side comparison card format suitable for use during patient encounters.</image>
Clinical Pearls
Blood pressure measurement is the only exam required before prescribing combined hormonal contraception; pelvic exam and Pap smear are not prerequisites. Quick-start contraception, meaning starting on the day of the visit, improves uptake and continuation rates compared to waiting for the next menstrual period. Migraine with aura is a Category 4 contraindication for estrogen-containing methods due to stroke risk, while migraine without aura is Category 2. The copper IUD is the most effective emergency contraception and can provide ongoing contraception for up to 10 years. LARC methods are safe for adolescents and nulliparous women, and prior misconceptions about IUDs and nulliparity have been debunked. Levonorgestrel emergency contraception has reduced efficacy in women weighing more than 75 kg, and ulipristal or the copper IUD should be offered instead. Continuous or extended cycling of combined pills is safe and eliminates withdrawal bleeding; there is no medical need for a monthly withdrawal bleed. The drospirenone progestin-only pill offers a wider dosing window than traditional norethindrone POPs, improving adherence and reducing missed-pill anxiety.
References
- Curtis KM et al. US Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR. 2016
- Curtis KM et al. US Selected Practice Recommendations for Contraceptive Use, 2016. MMWR. 2016
- ACOG Practice Bulletin No. 186: Long-Acting Reversible Contraception. Obstet Gynecol. 2017
- Turok DK et al. LNG-IUD vs. Copper IUD for Emergency Contraception. NEJM. 2021
- Trussell J et al. Contraceptive Efficacy. In: Contraceptive Technology. 22nd ed. 2024
- ACOG Committee Opinion: Access to Contraception. 2022
